Side and Razer unveil hybrid playtest and quality assurance tool with Artificial intelligence

Side and Razer announced a hybrid playtest and quality assurance tool that uses Side´s proprietary Artificial intelligence to run large-scale, targeted playtests inside Razer Cortex. The company says the approach could cut playtesting costs by up to 80% in some cases.

Side, an award-winning gaming services company, and Razer, the world´s leading lifestyle brand for gamers, revealed an industry disrupting playtest tool that pairs traditional playtesting with quality assurance. The product is powered by Side´s proprietary Artificial intelligence technology and is described as an industry first because playtest data is simultaneously used to improve quality assurance results. The announcement cites pricing comparisons from major playtest providers and states the combined approach could reduce playtesting costs by 80% in some cases.

Branded as Razer Cortex: Playtest Program – Powered by Side, the offering combines standard playtesting features with scaled QA capabilities to create an all-in-one testing solution for developers seeking both qualitative player feedback and technical issue discovery. The tool is designed to run large, targeted playtests with real players while capturing data that feeds automated QA processes. The companies position the integration as a way to deliver both user experience insights and technical validation from the same test events.

The playtest program will launch within Razer Cortex, Razer´s PC game launcher with over 55 million global users, giving developers access to a broad pool of testers. Side´s role centers on supplying the proprietary Artificial intelligence behind the simultaneous playtest and QA workflow. Together, the partners aim to streamline testing by consolidating qualitative and technical feedback channels and by offering a lower-cost alternative to separate playtesting and QA engagements. Further product details and availability are Not stated.

72

Impact Score

HMS researchers design Artificial Intelligence tool to quicken drug discovery

Harvard Medical School researchers unveiled PDGrapher, an Artificial Intelligence tool that identifies gene target combinations to reverse disease states up to 25 times faster than current methods. The Nature-published study outlines a shift from single-target screening to multi-gene intervention design.

Contact Us

Got questions? Use the form to contact us.

Contact Form

Clicking next sends a verification code to your email. After verifying, you can enter your message.